1   **Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study**

3   Michael Marks PhD, [1,2] Pere Millat-Martinez MD, [3] Dan Ouchi MSc, [4] Chrissy h. Roberts PhD, [1] Andrea
4   Alemany BM, [5] Marc Corbacho-Monné BM, [5] Maria Ubals MD,[6] Aurelio Tobias PhD [7], Cristian Tebé
5   PhD[8,9], Ester Ballana PhD[4,6], Martí Vall-Mayans PhD,[5,6] Camila G-Beiras PhD,[5]Nuria Prat MSc,[6] Jordi
6   Ara PhD,[6] Bonaventura Clotet PhD,[4,5,6,10] Oriol Mitjà PhD [5,6,9,10,11]
7

1. London School of Hygiene and Tropical Medicine, London, United Kingdom

2. Hospital for Tropical Diseases, London, United Kingdom

3. Barcelona Institute for Global Health – University of Barcelona, Barcelona, Spain

4. IrsiCaixa AIDS Research Institute, Badalona, Spain

5. Fight AIDS and Infectious Diseases Foundation, Badalona, Spain

6. Hospital Universitari Germans Trias i Pujol, Badalona Spain

7. Institute of Environmental Assessment and Water Research (IDAEA), Spanish Council for Scientific
Research (CSIC), Barcelona, Spain
16
17  8 Biostatistics Unit, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL),  L'Hospitalet de
18  Llobregat, Barcelona, Spain
19
20  9. Department of Clinical Sciences, Faculty of Medicine and Health Sciences, University of Barcelona ,
21  Barcelona, Spain.
22
10. Universitat de Vic – Universtiat Central de Catalunya, Vic, Spain

11. Lihir Medical Centre-InternationalSOS, Lihir Island, Papua New Guinea

Corresponding author: Michael Marks

Clinical Research Department,

London School of Hygiene & Tropical Medicine

London

United Kingdom

WC1E 7HT

# ABSTRACT

*Background*

There remains limited data on what variables affect risk of transmission of SARS-CoV-2 and developing symptomatic Covid-19 and in particular the relationship to viral load (VL). We analysed data from linked index cases and their contacts to explore factors associated with transmission of SARS-CoV-2.

*Methods*

Patients were recruited as part of a randomized control trial ,conducted between March to April 2020, that aimed to assess if hydroxychloroquine reduced transmission of SARS-CoV-2. Non-hospitalised Covid-19 cases and their contacts were identified through the local surveillance system. VL, measured by quantitative PCR from a nasopharyngeal swab, was assessed at enrollment, at day 14, and whenever the participant reported Covid-19-like symptoms. Risk of transmission, developing symptomatic disease and incubation dynamics were evaluated using regression analysis.

*Findings*

We identified 314 cases, 282 of which had at least one contact (753 contacts in total). Ninety (33%) of 282 clusters had at least one transmission event. The secondary attack rate was 16% (125/753), with a variation from 12% to 24% for VL of the index case of $<10^6$, and $>10^9$ copies/mL, respectively (OR per $\log_{10}$ increase in VL 1.3 95%CI 1.1–1.6). Increased risk of transmission was also associated with household contact (OR 2.7; 1.4–5.06) and age of the contact (OR 1.02 per year; 1.01–1.04). The proportion of PCR positive contacts who developed symptomatic Covid-19 was 40.3% (181/449), with a variation from 25% to 60% for VL of the contact $<10^7$, and $>10^9$ copies/mL (HR $\log_{10}$ increase in VL 1.12; 95% CI 1.05 – 1.2). Time to onset of symptomatic disease decreased from a median of 7 days (IQR 5–10) for individuals with an initial viral load $<10^7$ to 6 days (4–8) and 5 days (3–8) for individuals with an initial viral load of $10^7$–$10^9$ and $>10^9$, respectively.

*Interpretation*

Viral load of index cases is a leading driver of SARS-CoV-2 transmission. The risk of symptomatic Covid-19 is strongly associated with viral load of contacts at baseline and shortens the incubation time in a dose-dependent manner.

61   Funding: Crowdfunding campaign YoMeCorono (https://www.yomecorono.com/), and Generalitat de

62   Catalunya. Support for laboratory equipment from Foundation Dormeur.

# Research in context

*Evidence before this study*

In September 2020, we searched PubMed database for articles reporting on factors influencing transmission and the risk of developing symptomatic disease. Search terms included "Covid-19", "SARS-CoV-2", "transmission", "incubation time", and "risk", with no language restrictions. By 20th September, various authors had reported on retrospective analyses of clusters of index cases and their corresponding contacts, as well as series of patients who developed symptomatic Covid-19 disease after PCR positive result. Besides describing the secondary attack rate, various authors identified risk factors for transmission associated with the place and duration of exposure and the lack of use of personal protective equipment. A single study suggested that symptomatic individuals might be more likely to transmit than asymptomatic cases but we found no clear evidence regarding the influence of viral load of the index case on transmission risk. Similarly, although various retrospective series of patients with positive PCR results had reported incubation times elsewhere, the characteristics of index case and contacts that may influence the risk of developing symptomatic Covid-19 and the time to this event had been barely addressed.

*Added value of this study*

We analyzed data from a large cluster-randomized clinical trial on post-exposure therapy for Covid-19 that provide new information on SARS-CoV-2 transmission dynamics. Several design components add value to this dataset. Notably, quantitative PCR was available for the index cases to estimate risk of transmission. Furthermore, quantitative PCR was also performed on asymptomatic contacts at the time of enrollment allowing to investigate the dynamics of symptomatic disease onset among them. We found that the viral load of the index case was the leading determinant of the risk of SARS-CoV-2 PCR positivity among contacts. Among contacts who were SARS-CoV-2 PCR positive at baseline, viral load significantly influenced the risk of developing the symptomatic disease in a dose-dependent manner. This influence also became apparent in the incubation time, which shortened with increasing baseline viral loads.

*Implication of all the available evidence*

Our results provide important insights into the knowledge regarding the risk of SARS-CoV-2
transmission and Covid-19 development. The fact that the transmission risk is primarily driven by the
viral load of index cases, more than other factors such as their symptoms or age, suggests that all cases
should be considered potential transmitters irrespective of their presentation and encourages assessing
viral load in cases with a larger number of close contacts. Similarly, our results regarding the risk and
expected time to developing symptomatic Covid-19 encourage risk stratification of newly diagnosed
SARS-CoV-2 infections based on the initial viral load.

## INTRODUCTION

According to current evidence, Covid-19 is primarily transmitted from person to person through respiratory droplets, as well as indirect contact, through transfer of the virus from contaminated fomites to the mouth, nose, or eyes.[1,2] As with most respiratory viral infections there is likely to be some contribution from smaller aerosols but their relative contribution compared to droplets remains unclear. Several outbreak investigation reports have shown that Covid-19 transmission can be particularly effective in confined indoor spaces such as workplaces including factories, churches, restaurants, shopping centers, or healthcare settings.[3–6] In Spain, and many other countries, healthcare workers have experienced a high rate of Covid-19 infection.[7]

The availability of data regarding the factors that may enhance transmission is essential for designing interventions to control SARS-CoV-2 spread. Currently available data provide information on the risk of transmission related to the place and duration of exposure, and the use of respiratory and eye protection[1,3–5,8] but not on other factors related to the characteristics of index cases and their contacts. Over the course of infection, the virus has been identified in respiratory tract specimens 1–2 days before the onset of symptoms, and it can persist for prolonged periods over several weeks after the onset of symptoms in mild cases.[9] However, the detection of viral RNA by PCR does not necessarily equate with infectivity, and the exact relationship between viral load and risk of transmission from a case is still not clear.[10,11] Studies investigating case-contact pairs have reported highly variable secondary attack rates (i.e., range 0.7% to 75%), depending on the type of exposure—duration, place, pre- or post-symptomatic.[12–15]

Another challenge for public health interventions is the risk stratification of infected individuals for developing symptomatic illness. On the other hand, a living systematic review estimated that the proportion of PCR-positive infected contacts that progress to symptomatic disease is approximately 70-80%.[16,17] Estimates of mean or median incubation period have been consistently between 5–7 days.[18–20] Whilst there has been a suggestion that viral load of cases may potentially be associated with risk of disease or transmission there is currently no published data directly addressing this question and little is known about factors that may contribute to variation on the risk of developing Covid-19 symptoms or the incubation periods among infected individuals.

The overall aim of this study was to evaluate transmission dynamics of SARS-CoV-2 in the context of a trial of post-exposure prophylaxis. Specifically, the objectives of the study were threefold: (a) to investigate the association between clinical and demographic features of cases and viral load, (b) to evaluate the effect of viral load on SARS-CoV-2 transmission to close contacts, and (c) to determine the influence of viral load in the exposed on development of symptoms and on the incubation period.

**METHODS**

*Study design*

This was a post-hoc analysis of data collected in the BCN PEP CoV-2 Study (NCT04304053), a cluster-

randomized trial that included PCR-confirmed Covid-19 cases and their close contacts. The trial occurred

between Mar 17 to Apr 28, 2020, during the SARS-CoV-2 outbreak, in three out of nine healthcare areas

in Catalonia (North-East Spain): *Catalunya central, Àmbit Metropolità Nord, and Barcelona Ciutat,* total

target population 4,206,440 people. The study protocol of the BCN PEP CoV-2 Study was approved by

the ethics committee of Hospital Germans Trias Pujol, (Badalona, Spain). Written informed consent was

obtained from all participants. Full details of the original study are reported elsewhere.[21]

Covid-19 cases were identified using the electronic registry of the Epidemiological Surveillance

Emergency Service of Catalonia (SUVEC) of the Department of Health.[22] Following government

ordinance, the SUVEC registered all new Covid-19 diagnoses occurred from March 16, 2020. The

surveillance system included active tracing of all contacts with recent history of exposure, defined as

being in contact with a SARS-CoV-2 PCR positive case during more than 15 minutes within two meters.

All Covid-19 cases included in the present analysis were non-hospitalized adults (i.e., $\geq$ 18 years of age)

with quantitative PCR result available at baseline, mild symptom onset within five days before

enrollment, and no reported symptoms of SARS-CoV-2 infections in their accommodation (i.e.,

household or nursing home) or workplace within the 14 days before enrollment. Contacts selected for the

analysis were adults with a recent history of exposure and absence of Covid-19-like symptoms within the

seven days preceding enrolment. Contacts were exposed to the index case as either a healthcare worker, a

household contact, a nursing home worker, or a nursing home resident.

*Study procedures and data collection*

A dedicated outbreak field team visited cases and contacts at home or nursing home on days 1

(enrollment) and 14. At the first clinical assessment on day 1 they conducted a baseline assessment,

including a questionnaire for symptoms of Covid-19 and collected relevant epidemiological information

using a structured interview: time of first exposure to the index case, place of contact (hospital, home,

nursing care facility), routine use of a mask of both when in close proximity to the index case, the case

and the contact, and sleep location concerning the index case (e.g., same room, same house). Symptoms

surveillance consisted of active monitoring by phone on days 3, and 7, a home visit on day 14, and

passive monitoring whenever the participants developed symptoms. Participants who developed

symptoms were visited the same day they notified symptom onset (unscheduled visits) by the field team,

which recorded the date of symptom onset, type of symptoms from a pre-specified checklist, and
symptom severity, graded on a 1-to-4 scale.

Serial SARS-CoV-2 PCR test and viral load titration on nasopharyngeal swab were conducted on day 1
and day 14 to all participants, and on any unscheduled visit when the participant notified the onset of
Covid-19 symptoms. The detection of the SARS-CoV-2 virus was performed from nasopharyngeal swabs
at SYNLAB Diagnostics (Barcelona, Spain) by PCR using TaqMan™ 2019-nCoV Assay Kit according to
the manufacturer's protocol (Catalog number: A47532, Thermo Fischer Scientific Inc.). Viral load was
quantified from nasopharyngeal swabs at IrsiCaixa laboratory (Badalona, Spain) by PCR amplification,
based on the 2019-Novel Coronavirus Real-Time RT-PCR Diagnostic Panel guidelines and protocol
developed by the American Center for Disease Control and Prevention (CDC).[23] For absolute
quantification, a standard curve was built using 1/5 serial dilutions of a SARS-CoV2 plasmid (2019-
nCoV_N_Positive Control, catalog no. 10006625, $2 \times 10^5$ copies/μL, Integrated DNA Technologies) and
run in parallel to all PCR determinations.

*Outcomes and definitions*
Transmission was characterized by examining the number of infected and uninfected individuals among
close contacts to an index case. We defined transmission events as PCR-positivity at any time point (i.e.,
days 1, 14, or at any other unscheduled PCR testing when participants referred symptoms) of a contact in
the same household or workplace within the 14 days following enrollment. We defined the secondary
attack rate of viral transmission as the ratio of PCR-positive individuals among close contacts, according
to the WHO guidelines.

Development to symptomatic disease was defined as presence of at least one of the following symptoms:
fever, cough, difficulty breathing, myalgia, headache, sore throat, new olfactory and taste disorder(s), or
diarrhea) and a positive SARS-CoV-2 RT-PCR test. The incubation period was defined as time from first
exposure to symptom onset, with later confirmation of infection by PCR.[24] The earliest possible exposure
with the symptomatic index case was determined for each contact individually.

Study Participants

We selected all eligible individuals within the original trial population for each of the three analyses

conducted in the current study. As in the original trial there was no evidence of an impact of

hydroxychloroquine on either transmission or development of symptomatic disease we included

individuals in both arms of the trial in the current study. Firstly, all Covid-19 cases with quantitative PCR

data were included in an analysis of the association between clinical and demographic features of cases

and viral load. Secondly, we identified factors associated with transmission using all clusters of an index

case (i.e., a Covid-19 case with at least one close contact) and their corresponding contacts for which

quantitative viral load was available for the index case. Finally, we assessed the risk of developing

symptomatic disease and the variation in the incubation period amongst all contacts with a positive PCR

result at baseline, irrespective of available data of their index case.

*Statistical Analysis*

We used log transformed viral loads which were approximately normally distributed and which also align

with common reporting norms. The relationship between characteristics of cases and viral load was

assessed using linear regression considering age (in years), sex, the number of days from reported

symptom onset and the presence of absence of five key clinical features namely fever, cough, shortness of

breath or rhinitis and anosmia. To identify risk factors for transmission, we used logistic regression model

for the risk of transmission utilizing a random-effect model to allow for within cluster variation in the risk

of transmission. Factors with potential influence on the risk of transmission included characteristics of the

potential transmitter (i.e., age, sex, viral load, and the presence or absence of respiratory symptoms) and

contacts (i.e., age, sex, and the type of contact they had with the index case). Finally the risk of

developing symptomatic Covid-19 was assessed by fitting a cox-regression model considering the age (in

years) and sex of the individual, the presence or absence of cardiovascular disease, chronic respiratory

disease and the initial viral load in relation to the time to development of symptomatic disease. Data at 14

days after the first study visit were censored, in line with the follow-up conducted in the original trial. All

analyses were conducted in R version 4.0.

*Role of the funding source*

The funder of the study had no role in the study design, data collection, data analysis, data interpretation,

or writing of the report. All authors had full access to all the data in the study and had final responsibility

for the decision to submit for publication.

**RESULTS**

*Sample characteristics*

During the investigation period, we identified 314 cases in whom the viral load was tested. Overall, 220
(70.0%) were female and the median age was 41 (IQR 31-52). Of them, 282 had at least one close
contact, resulting in the corresponding clusters, with a total of 753 contacts. Clusters had a median of 2
contacts (IQR 1-3) and a maximum of 19 contacts. Most index cases of the clusters were female (n= 202,
71.6%), with an average age of 42 years (SD 13 years) (Table 1).

*Index case viral load*

The first study visit was performed a median of 4 days (IQR 3 -5) after symptom onset. At the first study
visit, the mean viral load amongst Covid-19 cases was $10^8$ ($10^{1.8}$). In multivariable linear regression the
viral load amongst cases was higher in individuals who reported fever (Table 2) and negatively associated
with the presence of anosmia but there was no association between the age or sex of the Covid-19 case
nor the presence of reported dyspnea or cough. As anticipated viral load was negatively associated with
the number of days since symptom onset.

*Cluster-level transmission*

For our risk factor analysis on SARS-CoV-2 transmission we used linked case and contact data of 282
clusters with 753 contacts. At the cluster level, 90 (33.3%) of the 282 clusters had at least one
transmission event, with a highly skewed distribution of the number of transmission events per cluster
(Figure 1A). The first visit for contacts took place a median of 5 days (IQR 4-7 days) after their first
possible exposure to the index case. A total of 125 (16.6%) of 753 contacts had a PCR positive result over
the study period. The proportion of contacts who tested positive for SARS-CoV-2 within a cluster
(secondary attack rate) progressively increased with the viral load of the index case: from 12% where the
index case had a viral load of $<10^6$ copies/mL to 24% where the index case had a viral load $>10^9$
copies/mL (Figure 1B). According to the multivariate analysis, the viral load of the index case was
strongly associated with the risk of onward transmission (OR per $log_{10}$ increase in VL 1.3; 95% CI 1.1-
1.6) (Table 3). Ninety percent (114/125) of transmission events had an index case viral load of 5.1 $log_{10}$
copies/ml or more, and 50% (61/125) had a viral load of 8.8 $log_{10}$ copies/ml or more. Other factors
associated with an increased risk of transmission were household contact (OR 2.7, 95% 1.4-5.06) and age
of the contact (OR 1.02, 95% 1.01-1.04). There was no association of risk of transmission with reported
mask usage by contacts, with the age or gender of the index case nor with the presence of respiratory
symptoms in the index case at the initial study visit (Table 3).

We did not find any evidence of an association between the viral load of the index cases and the first viral
load of incident positive results amongst contacts ($p = 0.1$, Supplementary Appendix) and this remained
true when adjusting for both the day of illness on which the index cases baseline viral load was measured
and the number of days until the contact was enrolled (p = 0.18). Also, after excluding contacts who were
PCR positive at the first study visit, we found no association between the viral load of the index case and
the time to onset of incident SARS-CoV-2 infection (HR 1.01 95% CI 0.83-1.23).

*Risk factor for Covid-19 disease among PCR+ contacts*

Overall, 449 contacts had a positive PCR result at first visit regardless of availability on viral load data of
their index case (n=125) or not (n=324). Twenty-eight (6.3%) of 449 contacts had symptoms at the first
visit and 181 (40.3%) developed symptomatic Covid-19 within the follow-up period. The multivariable
cox-regression analysis, after adjusting for age and sex, revealed that increasing viral load levels of the
contact at day 1 were associated with an increased risk of developing symptomatic disease. The risk of
symptomatic disease was approximately 25% amongst individuals with an initial viral load of $<10^7$
copies/mL compared to a more than 60% amongst those with an initial viral load of $>10^9$ (HR per $\log_{10}$
increase in VL 1.12; 95% CI 1.05 – 1.2; $p = 0.0006$) (Figure 2A). In the multivariable analysis there was
no association between sex or age of individuals nor the presence of diabetes, cardiovascular or
respiratory disease and the risk or time to developing symptomatic Covid-19.

The median time from exposure to symptom onset was 7 days (IQR 5 – 9). The time to onset of
symptomatic disease decreased from a median of 7 days (IQR 5 – 10) for individuals with an initial viral
load $<10^7$ copies/mL to 6 days (IQR 4 – 8) and 5 days (IQR 3 – 8) for individuals with an initial viral load
of $10^7$-$10^9$ and $>10^9$ copies/mL, respectively (Figure 2B).  Overall, 110/181 (60.8%) of participants who
developed symptoms did so before day 8, 45/181 (24.9%) between days 8-10, and 22/181 (12.2%)
between days 11-14.

**DISCUSSION**

In our study, we found that increasing viral load values in nasopharyngeal swabs of Covid-19 cases were
associated with the greater risk of transmission measured by SARS-CoV-2 PCR positivity among
contacts and also a higher risk of transmission in household environment compared to other indoor
situations. In addition, we found that higher viral loads in swabs of asymptomatic contacts were
associated with higher risk of developing symptomatic Covid-19 and have shorter incubation periods than
those with a lower viral load.  Relationships between viral load and infectivity  have been described for
other respiratory viruses and our study confirms the same is true for SARS-CoV-2.

To our knowledge this is the largest study that evaluates the relationship of viral load in Covid-19 cases

and risk of transmission. In our cohort, a high proportion (67%) of index cases did not cause secondary

infections. However, we identified 90 (33%) clusters with transmission events and the multivariate

analysis revealed that clusters centered on index cases with high viral load were significantly more likely

to result in transmission. Secondary attack rate was under 12% when the index case viral load was $<10^6$

copies/ml compared to more than 20% amongst clusters with the highest viral loads. In line with previous

analyses of case-contact clusters,[9,12,14] we also found that household exposure to an index case was

associated with a higher risk of transmission that other types of contact, presumably reflecting duration

and proximity of exposure. Age of the contact was also identified in our multivariate analysis as a

significant—albeit modest—determinant of transmission. This factor has shown uneven influence across

results reported elsewhere, but seems to play a secondary role among adults.[13,14] Finally, unlike previous

analyses that reported a relationship between coughing and transmission,[13] we did not find any

association. This finding suggests that the absence of cough does not preclude significant onward

transmission, particularly if the viral load is high. Taken together, our results indicate that the viral load,

rather than symptoms, may be the predominant driver of transmission.

Importantly, we report that high viral short after exposure in asymptomatic contacts was strongly

associated with the risk of developing symptomatic Covid-19 disease. We found an approximately 25%

chance of developing symptomatic disease amongst individuals with an initial viral load $<10^7$ copies/mL

compared to a more than 60% chance amongst individuals with a viral load $>10^9$. These data may provide

rationale for risk stratification for developing illness. Moreover, the initial viral load significantly shifted

the incubation time, which ranged from 5 days in participants with a high viral load to 7 days in

participants with a low viral load. Our study is the first analysis of prospective data that investigates the

association between initial viral load and the incubation time.

The study has several limitations. First, asymptomatic people were not enrolled as index cases, affecting

our ability to fully characterize all types of transmission chain. Second, we did not find any evidence of

decreased risk of transmission in individuals who reported mask use. While this finding collides with the

evidence reported elsewhere,[8] we did not have fine-grained data on type of mask (surgical vs FFP2), use

of other measures of PPE or other infection control practices, thus limiting our ability to make clear

inferences about the impact of PPE on transmission risk. Mask usage is likely correlated with type of

exposure which might further confound associations but we did not note any association between mask

use and risk either in our unadjusted analysis (Table 3) or in a multivariable model excluding type of

exposure (data not shown). Third, we used time to symptom onset (with later confirmation of infection)

rather than time to positive PCR test based on serial testing. Nonetheless, accurate calculation of the

incubation period was feasible because of the prospective nature of the study, accurate identification of exposure by face-to-face interview, and intensive active and passive monitoring of exposed contacts. We followed participants over 14-day periods, thus incubation periods beyond 14 days may not have been detected. Within each cluster we cannot be completely certain about the directionality of transmission, but our inclusion criteria including the absence of Covid-19 like symptoms in the 2 weeks proceeding enrolment is consistent with transmission from a case to a contact. We also cannot exclude that some individuals may have been infected by individuals outside of study clusters, but as per national guidelines all contacts were quarantined after exposure to index cases reducing the chance of transmission from elsewhere. Samples were available from index cases a median of four days after symptom onset and the initial sample in contacts was taken on average 5 days after exposure which may limit our ability to detect associations with peak viral load. Despite this we still demonstrate clear dose effects in relation to both risk of transmission and time to symptom onset. Finally, our study population is reflective of the trial from which the study sample is drawn and is therefore biased towards female participants, few comorbidities and predominantly mild-moderate infection and further data is needed on the risk of transmission in other populations.

In summary, our results provide evidence regarding the determinants of SARS-CoV-2 transmission, particularly on the role of the viral load. The higher risk of transmission among individuals with higher viral loads adds to current evidence and encourages assessing viral load in cases with a larger number of close contacts. When a case with high viral load is identified, implementation of reinforced contact tracing measures and quarantines, may be critical to reduce onward transmission. Similarly, our results regarding the risk and expected time to developing symptomatic Covid-19 encourage risk stratification of newly diagnosed SARS-CoV-2 infections based on the initial viral load.

## CONTRIBUTORS

MM, DO, OM accessed and verified the data. MM, DO, ChR, OM conceived of the study. MM performed the analysis. PM, AA, MCM, MU, MVM, CGB, NP, JA, BC, OM led the RCT from which study data is derived. MM and OM wrote the first draft of the manuscript. All authors gave critical input into interpretation and revised the manuscript.

## CONFLICTS OF INTEREST

We declare no conflicts of interest

## ACKNOWLEDGMENTS

The authors would like to thank Gerard Carot-Sans for providing medical writing support during the preparation of the manuscript.

## REFERENCES

La Rosa G, Bonadonna L, Lucentini L, Kenmoe S, Suffredini E. Coronavirus in water environments: Occurrence, persistence and concentration methods - A scoping review. *Water Res* 2020; **179**: 115899.

Umakanthan S, Sahu P, Ranade A V., *et al.* Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19). *Postgrad Med J* 2020; **0**: 1–6.

Leclerc QJ, Fuller NM, Knight LE, Funk S, Knight GM. What settings have been linked to SARS-CoV-2 transmission clusters? *Wellcome Open Res* 2020; **5**: 83.

Qian H, Miao T, LIU L, Zheng X, Luo D, Li Y. Indoor transmission of SARS-CoV-2. *medRxiv* 2020; : 2020.04.04.20053058.

Hamner L, Dubbel P, Capron I, *et al.* High SARS-CoV-2 Attack Rate Following Exposure at a Choir Practice — Skagit County, Washington, March 2020. *MMWR Morb Mortal Wkly Rep* 2020; **69**: 606–10.

Park SY, Kim YM, Yi S, *et al.* Coronavirus disease outbreak in call center, South Korea. *Emerg Infect Dis* 2020; **26**: 1666–70.

Muñoz MA, López-Grau M. Lessons learned from the approach to the COVID-19 pandemic in urban primary health care centres in Barcelona, Spain. *Eur J Gen Pract* 2020; **26**: 106–7.

Chu DK, Akl EA, Duda S, *et al.* Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. *The Lancet* 2020; **395**: 1973–87.

Bi Q, Wu Y, Mei S, *et al.* Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. *Lancet Infect Dis* 2020; **20**: 911–9.

Wölfel R, Corman VM, Guggemos W, *et al.* Virological assessment of hospitalized patients with COVID-2019. *Nature* 2020; **581**: 465–9.

La Scola B, Le Bideau M, Andreani J, *et al.* Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. *Eur J Clin Microbiol Infect Dis* 2020; **39**: 1059–61.

12 Böhmer MM, Buchholz U, Corman VM, *et al.* Investigation of a COVID-19 outbreak in Germany
resulting from a single travel-associated primary case: a case series. *Lancet Infect Dis* 2020; **20**: 920–8.

13 Wu J, Huang Y, Tu C, *et al.* Household Transmission of SARS-CoV-2, Zhuhai, China, 2020. *Clin*
*Infect Dis* 2020; published online May 11. DOI:10.1093/cid/ciaa557.

14 Cheng HY, Jian SW, Liu DP, Ng TC, Huang WT, Lin HH. Contact Tracing Assessment of COVID-19
Transmission Dynamics in Taiwan and Risk at Different Exposure Periods before and after Symptom
Onset. *JAMA Intern Med* 2020; **180**: 1156–63.

15 Huang L, Zhang X, Zhang X, *et al.* Rapid asymptomatic transmission of COVID-19 during the
incubation period demonstrating strong infectivity in a cluster of youngsters aged 16-23 years outside
Wuhan and characteristics of young patients with COVID-19: A prospective contact-tracing study. *J*
*Infect* 2020; **80**: e1–13.

16 Liu T, Gong D, Xiao J, *et al.* Cluster infections play important roles in the rapid evolution of COVID-
19 transmission: a systematic review. *Int J Infect Dis* 2020; **99**: 374.

17 Buitrago-Garcia D, Egli-Gany D, Counotte MJ, *et al.* Occurrence and transmission potential of
asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-
analysis. *PLOS Med* 2020; **17**: e1003346.

18 Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel coronavirus (2019- nCoV)
infections among travellers from Wuhan, China, 20 28 January 2020. *Eurosurveillance* 2020; **25**: 20–
8.

19 Li Q, Guan X, Wu P, *et al.* Early transmission dynamics in Wuhan, China, of novel coronavirus-
infected pneumonia. *N Engl J Med* 2020; **382**: 1199–207.

20 Leung C. The difference in the incubation period of 2019 novel coronavirus (SARS-CoV-2) infection
between travelers to Hubei and nontravelers: The need for a longer quarantine period. *Infect Control*
*Hosp Epidemiol* 2020; **41**: 594–6.

21 Mitja O, Ubals M, Corbacho M, *et al.* A Cluster-Randomized Trial of Hydroxychloroquine as
Prevention of Covid-19 Transmission and Disease. *medRxiv* 2020; : 2020.07.20.20157651.

22 Catalan Ministry of Health. Catalan epidemiological surveillance system.
http://salutpublica.gencat.cat/ca/ambits/vigilancia_salut_publica/ (accessed March 28, 2020).

23 Centers for Disease Control and Prevention (CDC). CDC 2019-Novel Coronavirus (2019-nCoV) Real-
Time RT-PCR Diagnostic Panel. Cat. 2019-NCoVEUA-01. 2020.
https://www.fda.gov/media/134922/download (accessed May 21, 2020).

24 World Health Organization. The First Few X (FFX) Cases and contact investigation protocol for 2019-
novel coronavirus (2019-nCoV) infection, version 2. https://www.who.int/publications/i/item/the-first-
few-x-(ffx)-cases-and-contact-investigation-protocol-for-2019-novel-coronavirus-(2019-ncov)-
infection (accessed Sept 21, 2020).

**Tables**

**Table 1:**

**Baseline Characteristics of linked transmission clusters**

| Variable | | Value |
|---|---|---|
| Cluster Size | Median (IQR) | 2 (1-3) |
| Index Case Age | Years – Mean (SD) | 42 (13) |
| Index Case Sex | Female (%) | 202 (64.%) |
| Index Case Log Viral Load | Mean (SD) | 8 (1.8) |
| Contacts Age | Years – Mean (SD) | 42 (15) |
| Contacts Gender | Female (%) | 385 (51.1%) |
| | Male (%) | 305 (40.5%) |
| | Missing (%) | 63 (8.4%) |
| Baseline PCR of Contact Case | Positive | 93 (14.2%) |
| Contact | HCW | 254 (33.7%) |
| | Household | 382 (50.7%) |
| | Nursing Home | 21 (2.8%) |
| | Unknown | 96 (12.7%) |

417 **Table 2: Univariable and multivariable linear regression of association between Index case**
418 **variables and log$_{10}$ viral load**

| Characteristic | | Log$_{10}$ Viral Load/ml | Unadjusted β coefficient (95% CI) | p | Adjusted β coefficient (95% CI) | p |
|---|---|---|---|---|---|---|
| Case Age | | N/A | 0.002 (-0.02 – 0.02) | 0.78 | 0.008 (-0.01 – 0.02) | 0.38 |
| Case Sex | Male | 8.15 (7.54 – 8.77) | Reference | | Reference | |
| | Female | 8.04 (7.47 – 8.6) | -0.238 (-0.72 – 2.4) | 0.33 | -0.22 (-0.61 – 0.34) | 0.59 |
| Days from Symptom Onset | | NA | -0.17 (-0.26 – 0.0.8) | 0.0002 | -0.16 (-0.24 – 0.07) | 0.0004 |
| Cough | Absent | 7.82 (7.24 – 8.41) | Reference | | Reference | |
| | Present | 8.37 (7.78 – 8.95) | 0.66 (0.22 – 1.1) | 0.003 | 0.41 (-0.02 – 0.84) | 0.06 |
| Dyspnea | Absent | 7.97 (7.5-8.43) | Reference | | Reference | |
| | Present | 8.22 (7.45-8.99( | 0.27 (-0.40 – 0.94) | 0.42 | 0.28 (-0.35 – 0.92) | 0.38 |
| Fever | Absent | 7.77 (7.16 – 8.38) | Reference | | Reference | |
| | Present | 8.42 (7.86-8.98) | 0.80 (0.36 – 1.24) | 0.0004 | 0.43 (0.00 – 0.87) | 0.05 |
| Anosmia | Absent | 8.32 (7.76 – 8.88) | Reference | | Reference | |
| | Present | 7.87 (7.25-8.49) | -0.57 (-1.0 - -0.09) | 0.02 | -0.54 (-1.0 – 0.09) | 0.02 |
| Rhinits | Absent | 7.60 (7.23 – 7.98) | Reference | | Reference | |
| | Present | 8.59 (7.65-9.52) | 0.88 (-0.05 – 1.82) | 0.06 | 0.77 (-0.11 – 1.66) | 0.09 |

**Table 3: Risk factors for transmission of SARS-CoV-2**

|  |  | **Unadjusted Odds Ratio** | **Confidence Interval** | **p** | **Adjusted Odds Ratio** | **Confidence Interval** | **p** |
|---|---|---|---|---|---|---|---|
| Index case age (per year) |  | 1.02 | 0.99-1.05 | 0.07 | 1 | 0.99-1.03 | 0.46 |
| Female Index Case |  | 0.74 | 0.4-1.36 | 0.33 | 0.71 | 0.37-1.39 | 0.32 |
| Index Case Viral Load (per $Log_{10}$ change) |  | 1.27 | 1.09-1.48 | <0.01 | 1.29 | 1.1-1.5 | 0.001 |
| Index Case Cough |  | 1.0 | 0.55-1.82 | 0.99 | 1.13 | 0.64 – 2.0 | 0.66 |
| Index Case Dyspnea |  | 0.80 | 0.31-2.07 | 0.64 | 0.75 | 0.30 – 1.89 | 0.55 |
| Index Case Rhinitis |  | 1.46 | 0.46-4.63 | 0.52 | 1.31 | 0.42-4.11 | 0.64 |
| Age of Contact |  | 1.03 | 1.01-1.05 | <0.01 | 1.02 | 1.01 – 1.04 | 0.0008 |
| Female Contact |  | 0.93 | 0.58-1.49 | 0.77 | 1.33 | 0.79 – 2.23 | 0.28 |
| Mask Use | Never | 1 (Reference Group) | N/A | N/A | 1 (Reference Group) | N/A | N/A |
|  | Always | 0.93 | 0.47 – 1.83 | 0.84 | 1.55 | 0.76 – 3.16 | 0.23 |
|  | Unknown | 1.18 | 0.59 – 2.36 | 0.47 | 1.49 | 0.74-3.01 | 0.0.26 |
| Contact Type | Healthcare Work | 1 (Reference Group) | N/A | N/A | 1 (Reference Group) | N/A | N/A |
|  | Household | 3.07 | 1.68-5.62 | <0.01 | 3.0 | 1.59 – 5.65 | 0.0006 |
|  | Nursing Home | 1.75 | 0.19 -16.01 | 0.62 | 1.90 | 0.30 – 11.91 | 0.49 |
|  | Other | 0.32 | 0.03-3.05 | 0.32 | 1.19 | 0.10 – 14.31 | 0.89 |

**Figure 1: Transmission in a cluster**

(A) Number of secondary cases per cluster. (B) Relationship between viral load of the index case and the

proportion of contacts developing Covid-19. Numbers 18/149 in group $10^4$-$10^5$ RNA copies/ml; 30/2012

in group $10^6$-$10^7$; 59/298 in group $10^8$-$10^9$; 17/71 in group $\geq 10^{10}$.

**Figure 2. Risk of developing symptomatic Covid-19 according to characteristics of the contact at**

**enrolment.**

(A) probability of symptomatic disease by viral load. (B) time to symptomatic disease by viral load.

## Data Sharing Statement

Marks M, Millat-Martinez P, Ouchi d et al. Transmission of Covid-19 in 282 clusters in
Catalonia, Spain: a cohort study
442
443
444

| Question | Authors' Response |
|---|---|
| Will the data collected for your study be made available to others? | Yes |
| Which data? | Complete de-identified patient data set |
| Will any supporting documents be available? | Study protocol |
| | |
| How or where can the data be obtained? | mcorbacho@flsida.org |
| When will data availability begin? | 15/12/2020 |
| When will data availability end? | 15/12/2021 |
| To whom will data be available? | Researchers whose proposed use of the data has been approved |
| For what type of analysis or purpose? | For any purpose |
| By what mechanism? | By email |
| Any other restrictions? | — |
| Additional information | — |

445
446
447